Literature DB >> 15576745

Clomipramine induced neuroleptic malignant syndrome and pyrexia of unknown origin.

Alison M Haddow1, Dawn Harris, Martin Wilson, Hannah Logie.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15576745      PMCID： PMC534848          DOI： 10.1136/bmj.329.7478.1333

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  19 in total

Review 1.  Neuroleptic malignant syndrome.

Authors:  P Adnet; P Lestavel; R Krivosic-Horber
Journal:  Br J Anaesth       Date:  2000-07       Impact factor: 9.166

2.  Neuroleptic malignant syndrome after addition of paroxetine to olanzapine.

Authors:  Vassilis P Kontaxakis; Beata J Havaki-Kontaxaki; Dimitra A Pappa; Dimosthenis E Katritsis; George N Christodoulou
Journal:  J Clin Psychopharmacol       Date:  2003-12       Impact factor: 3.153

3.  Pharmacological profile of antidepressants and related compounds at human monoamine transporters.

Authors:  M Tatsumi; K Groshan; R D Blakely; E Richelson
Journal:  Eur J Pharmacol       Date:  1997-12-11       Impact factor: 4.432

4.  Neuroleptic sensitivity in dementia with Lewy bodies and Alzheimer's disease.

Authors:  C Ballard; J Grace; I McKeith; C Holmes
Journal:  Lancet       Date:  1998-04-04       Impact factor: 79.321

Review 5.  Selective serotonin reuptake inhibitor-induced serotonin syndrome: review.

Authors:  R Lane; D Baldwin
Journal:  J Clin Psychopharmacol       Date:  1997-06       Impact factor: 3.153

6.  Severe hyperthermia during tetrabenazine therapy for tardive dyskinesia.

Authors:  E Stevens; A Roman; M Houa; D Razavi; N Jaspar
Journal:  Intensive Care Med       Date:  1998-04       Impact factor: 17.440

7.  Ecstasy, the serotonin syndrome, and neuroleptic malignant syndrome--a possible link?

Authors:  D Ames; W C Wirshing
Journal:  JAMA       Date:  1993-02-17       Impact factor: 56.272

8.  Frequency of neuroleptic malignant syndrome in a large psychiatric hospital in Moscow.

Authors:  B Spivak; D I Maline; V N Kozyrev; R Mester; S A Neduva; R S Ravilov; A Weizman
Journal:  Eur Psychiatry       Date:  2000-08       Impact factor: 5.361

Review 9.  Incidence and risk factors in neuroleptic malignant syndrome.

Authors:  H Naganuma; I Fujii
Journal:  Acta Psychiatr Scand       Date:  1994-12       Impact factor: 6.392

Review 10.  Genetic predisposition to neuroleptic malignant syndrome : implications for antipsychotic therapy.

Authors:  Chiaki Kawanishi
Journal:  Am J Pharmacogenomics       Date:  2003
View more
  5 in total

1.  Clomipramine and neuroleptic malignant syndrome: literature on adverse reactions to psychotropic drugs continues to confuse.

Authors:  Geoffrey K Isbister; Nicholas A Buckley
Journal:  BMJ       Date:  2005-04-02

Review 2.  Pain management in neurocritical care.

Authors:  Axel Petzold; Armand Girbes
Journal:  Neurocrit Care       Date:  2013-10       Impact factor: 3.210

Review 3.  Neuroleptic malignant syndrome: an easily overlooked neurologic emergency.

Authors:  Ramadhan Oruch; Ian F Pryme; Bernt A Engelsen; Anders Lund
Journal:  Neuropsychiatr Dis Treat       Date:  2017-01-16       Impact factor: 2.570

4.  Neuroleptic malignant syndrome secondary to olanzapine, a presentation with severe acute kidney injury requiring hemodialysis: a case report.

Authors:  Chee Keong Chang; Alvin Oliver Payus; Malehah Mohd Noh; Meryl Grace Lansing; Doreen Sumpat; Sooth Jiun Andrea Lu; Boon Teong Yew
Journal:  J Med Case Rep       Date:  2022-10-06

5.  Neurotoxic syndrome induced by clomipramine plus risperidone in a patient with autistic spectrum disorder: serotonin or neuroleptic malignant syndrome?

Authors:  Kalliopi N Nikolaou; Rossetos Gournellis; Ioannis Michopoulos; Georgios Dervenoulas; Christos Christodoulou; Athanasios Douzenis
Journal:  Ann Gen Psychiatry       Date:  2015-11-14       Impact factor: 3.455
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.